Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common mucus-thinning drugs may improve outcomes in COPD patients with lung cancer

NCT ID NCT07712016

Ongoing Knowledge-focused Sponsor: Seoul National University Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study looks at whether taking muco-active agents (mucus-thinning drugs like N-acetylcysteine and ambroxol) after a lung cancer diagnosis is linked to better outcomes in people who also have COPD. Researchers will analyze data from a large Korean database, comparing those who started these drugs shortly after diagnosis to those who did not. The main focus is on whether these drugs reduce the risk of moderate-to-severe COPD flare-ups and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
muco-active agents (mucolytics, expectorants, and mucokinetics such as N-acetylcysteine, erdosteine, carbocysteine, guaifenesin, ivy-leaf extract, ambroxol, and bromhexine)
What this could lead to
If the study finds a link, it could suggest that using these common mucus-thinning drugs after a lung cancer diagnosis might help people with COPD have fewer flare-ups and live longer.
What could go wrong
This is an observational study using existing data, not a controlled experiment. It can only show an association, not prove cause and effect, and results may be influenced by unmeasured differences between groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset disease Disease Progression lung cancer lung disorder lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) LUNG CANCER (DIAGNOSIS)

Contacts and locations

Locations

  • National Cancer Center,

    Goyang-si, Gyeonggi-do, 10408, South Korea

  • Seoul National University College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center

    Seoul, Select..., 07061, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.